Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).

Journal: American journal of clinical dermatology

Publication Year: 

Authors & Co-authors:  Silverberg Gooderham Paller Deleuran Bunick Gold Hijnen Calimlim Lee Teixeira